Pipecuronium Bromide (Arduan)

  • E. Tassonyi
  • G. Szabó
  • L. Vimláti
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 79)


Muscle relaxants belong to the basic anesthetic drugs and it is quite understandable that newer compounds have come into being. Among these drugs, steroid derivatives have an important place and, besides pancuronium, many similarly structured muscle relaxants have been tried in the past few years (Sugrue et al. 1975; Bowman 1980; Tuba 1980).


Impaired Renal Function Neuromuscular Blocking Pancuronium Bromide Clinical Duration Neuromuscular Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alánt O, Darvas K, Pulay I (1980) First clinical experience with a new neuromuscular blocker pipecuronium bromide. Arzneimittelforsch 20:374–379Google Scholar
  2. Alyantdin RN, Buyanon VV, Fisenco VP, Lemina E, Muratov VK, Samoilov DN, Shorr VA (1980) On some properties of a new steroidal curare-like compound pipecuronium bromide. Arzneimittelforsch 30:355–357Google Scholar
  3. Barankay A (1980) Circulatory effects of pipecuronium bromide during anesthesia of patients with severe valvular and ischemic heart diseases. Arzneimittelforsch 30:386–389PubMedGoogle Scholar
  4. Bodrogi L, Fehér T, Váradi A, Vereckey L (1980) Pharmacokinetics of pipecuronium bromide in the rat. Arzneimittelforsch 30:366–370PubMedGoogle Scholar
  5. Boros M, Szenohradszky J, Marosi GY, Tóth J (1980) Comparative clinical study of pipecuronium bromide and pancuronium bromide. Arzneimittelforsch 30:389–393PubMedGoogle Scholar
  6. Bowman WC (1980) A new non-depolarizing neuromuscular blocking drug. Trends Pharm Sci 3:263–266CrossRefGoogle Scholar
  7. Brand L (1978) Hemodynamic changes due to anesthesia using curare and curarizing agent. In: Hemodynamic changes in anesthesia, vol 3. Academic Européene d’Anesthesiolo-gie, Paris, pp 1123–1135Google Scholar
  8. Bunjatjan AA, Miheev VI (1980) Clinical experience with a new steroid muscle relaxant: pipecuronium bromide. Arzneimittelforsch 30:383–385PubMedGoogle Scholar
  9. Buzello W, Agoston S (1978) Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Anaesthesist 27:291–297PubMedGoogle Scholar
  10. Coleman AJ, Downing JW, Leary WP, Moyes DG, Styles M (1972) The immediate cardiovascular effects of pancuronium alcuronium and tubocurarine in man. Anesthesia 27:415–421CrossRefGoogle Scholar
  11. Fahey MR, Morris RB, Miller RD, Nguyen TL, Upton RA (1981) Pharmacokinetics of Org NC 45 (Norcuron) in patients with and without renal failure. Br J Anaesth 53:1049–1054PubMedCrossRefGoogle Scholar
  12. Foldes FF, Chaudry J, Ohta Y et al. (1981) The influence of stimulation parameters on the potency and reversibility of neuromuscular blocking agents. J Neural Transm 52:227–249PubMedCrossRefGoogle Scholar
  13. Kárpáti E, Biró K (1980) Pharmacological study of a new competitive neuromuscular blocking steroid, pipecuronium bromide. Arzneimittelforsch 30:346–354PubMedGoogle Scholar
  14. Kelman GR, Kennedy BR (1971) Cardiovascular effects of pancuronium in man. Br J Anaesth 43:335–356PubMedCrossRefGoogle Scholar
  15. Krieg N, Crull JF, Booij LMD (1980) Relative potency of Org NC 45, pancuronium, alcuronium and tubocurarine in anesthetized man. Br J Anaesth 52:783–794PubMedCrossRefGoogle Scholar
  16. McLoad K, Watson MJ, Rawlins MD (1976) Pharmacokinetics of pancuronium in patients with normal and impaired renal function. Br J Anaesth 48:341–349CrossRefGoogle Scholar
  17. Pulay I, Alánt O, Darvas K, Weltner J, Zétény ZS (1980) Respiration paralysing and circulatory effects of a new non-depolarizing relaxant, pipecuronium bromide, in anesthetized dogs. Arzneimittelforsch 30:358–360PubMedGoogle Scholar
  18. Somogyi AA, Shanks CA, Triggs EJ (1976) Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol 10:367–372PubMedCrossRefGoogle Scholar
  19. Somogyi AA, Shanks CA, Triggs EJ (1977) Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 49:1103–1107PubMedCrossRefGoogle Scholar
  20. Stanski DR, Sneider LB (1979) Pharmacokinetics and dynamics of muscle relaxants. Anesthesiology 51:103–105PubMedCrossRefGoogle Scholar
  21. Stoelting RK (1972) The hemodynamic effects of pancuronium and d-tubocurarine in anesthetized patients. Anesthesiology 36:612–618PubMedCrossRefGoogle Scholar
  22. Sugrue MF, Duff N, McInderwar J (1975) On the pharmacology of Org 6368 [2β,16β-diperidino-5α-androstan-3α-ol acetate dimethobromide], a new steroidal neuromuscular blocking agent. J Pharm Pharmacol 27:721–727PubMedCrossRefGoogle Scholar
  23. Szabó G, Tassonyi E (1981) Determination of pipecuronium bromide, a new non-depolarizing neuromuscular blocking agent, in human serum. Arzneimittelforsch 31:1013–1015PubMedGoogle Scholar
  24. Tassonyi E, Szabó G (1977) Correlation entre le bloc n-m et taux serique du pancuronium. Central European Anaesthesia Congress, Genova, p 3351Google Scholar
  25. Tassonyi E, Szabó G (1981) Pharmakokinetische und pharmakodynamische Untersuchungen mit einem neuen steroidartigen Muskelrelaxans. In: Haid HB, Mitterschiffthaler G (eds) Zentraleuropäischer Anaesthesiekongreß 2. Springer, Berlin Heidelberg New York (Anaesthesiology and intensive care medicine, vol 140)Google Scholar
  26. Tassonyi E, Szabó G, Vereckey L (1980) Pharmacokinetics of pipecuronium bromide in patients with renal failure. In: Rügheimer E, Wawersik J, Zindler M (eds) 7th World congress of anaesthesiologists. Excerpta Medica, Amsterdam, p 168 (International congress series, no 533)Google Scholar
  27. Tassonyi E, Szabó G, Vereckey L (1981) Pharmacokinetics of pipecuronium bromide, a new non-depolarizing neuromuscular blocking agent, in humans. Arzneimittelforsch 31:1754–1756PubMedGoogle Scholar
  28. Tuba Z (1980) Synthesis of 2β,16β-bis[4′-dimethyl-1-piperazino]-3α,17β-diacetoxy-5α-androstane di-bromide and related compounds. Arzneimittelforsch 30:342–345PubMedGoogle Scholar
  29. Westra P, Houwertjes MC, DeLange AR, Scaf AH, Hindriks FR, Agoston S (1980) Effect of experimental cholestasis on neuromuscular blocking drugs in cats. Br J Anaesth 52:747–756PubMedCrossRefGoogle Scholar
  30. Wittek L, Gecsényi M, Barna B, Hargitay Z, Adorján K (1980) Report on clinical test of pipecuronium bromide. Arzneimittelforsch 30:379–383PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • E. Tassonyi
  • G. Szabó
  • L. Vimláti

There are no affiliations available

Personalised recommendations